Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio presented 36-week Part B results from the SIGNAL-AA Phase 2a trial of bempikibart in severe alopecia areata at the EADV 2026 congress as a late-breaker, showing a mean SALT score reduction of 35.3% and SALT-20 responses in 40% of mITT patients. Durability was a highlight: in the 16-week off-drug period, 44% of patients maintained SALT-20 and 100% of Week-36 responders maintained response, supporting potential less frequent chronic maintenance dosing.
Key figures
- Drug Name
- bempikibart (ADX-914)
- Phase Of Trial
- Phase 2a
- Offdrug salt20
- 44%
- Offdrug salt30
- 61%
- Offdrug salt50
- 50%
- Patients enrolled
- 33
- Salt20 response itt
- 30.3% (10/33)
- Salt20 response mitt
- 40.0% (10/25)
- Salt30 response mitt
- 44.0%
- Salt50 response mitt
- 44.0%
- Isr treatment emergent
- 36.3%
- Mean salt reduction mitt
- 35.3%
- Registrational program start
- first half of 2027
- Mean salt reduction jak naive
- 44.1%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.